Back to top

oncology-screening: Archive

Zacks Equity Research

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.

CRMDNegative Net Change ARVNPositive Net Change IMCRPositive Net Change RXRXNegative Net Change

Zacks Equity Research

Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?

RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.

ZTSNegative Net Change ACADNegative Net Change RXRXNegative Net Change

Shaun Pruitt

3 Medical Stocks to Consider as Markets Take a Breather

These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.

JNJNegative Net Change THCNegative Net Change CVSPositive Net Change